Skip to content
The Nexus
DossierENTITY

Part D redesign

Coverage of Part D redesign in the Nexus archive.

Earliest in view: Jun 11 · 14:11 UTCMost recent: Jun 11 · 14:11 UTC
Co-mentioned in this coverage
Novartisorganization1molecular glue strategytopic1Enlivenorganization1leukemia drugtopic1SonoTheraorganization1Medicareorganization1GLP-1 medicinestopic1
Recent coverage
  • HEALTHJun 11 · 14:11 UTCSTAT NEWS
    STAT+: Novartis doubles down on molecular glue strategy

    Novartis is expanding its molecular glue strategy, Enliven's leukemia drug shows encouraging early data, and SonoThera raised $125 million for an ultrasound-based gene delivery approach. Medicare drug spending is rising faster than expected due to increased GLP-1 medicine use and the Democrats’ Part D redesign.